Limited-Stage Hodgkin Lymphoma Minimizing Toxicity

被引:2
|
作者
Straus, David J. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Lymphoma Serv, 1275 York Ave,Box 330, New York, NY 10065 USA
[2] Weill Cornell Med, New York, NY USA
关键词
chemotherapy; combined modality; early-stage classic Hodgkin lymphoma; long-term toxicity; radiation; RADIATION-THERAPY; HEART-DISEASE; HD15; TRIAL; OPEN-LABEL; CHEMOTHERAPY; RADIOTHERAPY; RISK; ABVD; DACARBAZINE; TOMOGRAPHY;
D O I
10.1097/PPO.0000000000000329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.
引用
收藏
页码:223 / 229
页数:7
相关论文
共 50 条
  • [21] Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma
    Macdonald, D. A.
    Ding, K.
    Gospodarowicz, M. K.
    Wells, W. A.
    Pearcey, R. G.
    Connors, J. M.
    Winter, J. N.
    Horning, S. J.
    Djurfeldt, M. S.
    Shepherd, L. E.
    Meyer, R. M.
    ANNALS OF ONCOLOGY, 2007, 18 (10) : 1680 - 1684
  • [22] Does Limited-Stage Diffuse Large B-Cell Lymphoma (LS-DLBCL) Matter?
    Martynchyk, Arina
    Hawkes, Eliza A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S44 - S46
  • [23] Treatment of advanced-stage Hodgkin lymphoma
    Engert, Andreas
    HEMATOLOGICAL ONCOLOGY, 2015, 33 : 87 - 89
  • [24] Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD
    Villa, Diego
    Sehn, Laurie H.
    Aquino-Parsons, Christina
    Tonseth, Petter
    Scott, David W.
    Gerrie, Alina S.
    Wilson, Donald
    Benard, Francois
    Gascoyne, Randy D.
    Slack, Graham W.
    Farinha, Pedro
    Morris, James
    Pickles, Tom
    Connors, Joseph M.
    Savage, Kerry J.
    HAEMATOLOGICA, 2018, 103 (12) : E590 - E593
  • [25] Chemotherapy alone versus chemotherapy followed by consolidative radiotherapy for limited-stage aggressive non-Hodgkin's lymphoma: A meta-analysis of randomized controlled trials
    Huang, Z.
    Xu, Z.
    Zhou, Y.
    CANCER RADIOTHERAPIE, 2013, 17 (08): : 736 - 743
  • [26] Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era
    Taparra, Kekoa
    Liu, Heshan
    Polley, Mei-Yin
    Ristow, Kay
    Habermann, Thomas M.
    Ansell, Stephen M.
    LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 298 - 308
  • [27] Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma
    Pinnix, Chelsea C.
    Milgrom, Sarah A.
    Cheah, Chan Yoon
    Gunther, Jillian R.
    Ludmir, Ethan B.
    Wogan, Christine F.
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Westin, Jason
    Lee, Hun J.
    Iyer, Swaminathan P.
    Steiner, Raphael E.
    Fayad, Luis E.
    Fowler, Nathan H.
    Wang, Michael L.
    Samaniego, Felipe
    Rodriguez, Maria A.
    Rich, Amy E.
    Medeiros, L. Jeffrey
    Dabaja, Bouthaina S.
    BLOOD ADVANCES, 2019, 3 (09) : 1356 - 1367
  • [28] Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?
    Basaran, Gul
    Agaoglu, Fulya
    Basaran, Mert
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : E485 - E486
  • [29] Treatment Strategies in Advanced-Stage Hodgkin Lymphoma
    Dann, Eldad J.
    Casasnovas, Rene-Olivier
    CANCERS, 2024, 16 (11)
  • [30] Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
    Fiaccadori, Valeria
    Neven, Anouk
    Fortpied, Catherine
    Aurer, Igor
    Andre, Marc
    Federico, Massimo
    Counsell, Nicholas
    Phillips, Elizabeth H.
    Clifton-Hadley, Laura
    Barrington, Sally F.
    Illidge, Timothy
    Radford, John
    Raemaekers, John M. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (06) : 731 - 739